Study on the Safety and Effectiveness of VELCADE® in the Treatment of Graft-Versus-Host Disease

NCT00408928 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

11

Enrollment

OTHER

Sponsor class

Conditions

Graft-versus-Host Disease

Interventions

DRUG: Bortezomib

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University